SWOG clinical trial number
S0229
A Randomized Trial Assessing the Effects of Exercise on Patients with Locally Advanced Lung Cancer Undergoing Curative Intent Combined Modality Therapy
Closed
Phase
Accrual
1%
Research committees
Lung Cancer
Eligibility Criteria Expand/Collapse
Pts must have unresectable Stage IIIA (N2) or Stage IIIB lung cancer of any histology including small cell lung cancer. All pts must have received platin-based chemo & RT (>4,500cGy using CT planning)and recovered from acute side effects. All pts must be re-staged 4-8 wks after completion of treatment and have CR/PR/SD at re-staging to be eligible. Pts must be willing to take part in an exercise program of 12 wks including F/U visits if they are randomized to that arm of the study. Pts must have a Zubrod PS 0-2 and be physically capable of participating. No uncontrolled cardiac disease, recent MI, uncontrolled diabetes mellitus or any other medical conditions that would preclude part in the exercise program. Pts with chemotherapy induced neuropathy must have <= Grade 2 by CTCAE Version 3.0. PFT must be performed w/in 28 days prior to reg. Pts must be able to read and understand English in order to participate in the QOL portion of the study. Pts unable to read and understand English may be reg to receive the exercise or standard medical management intervention w/o completing the QOL questionnaire. Pts able to read and understand English must have completed the FACT-L TOI no more than 14 days before reg. The nurse or CRA must have completed the QOL Cover Sheet for the pre-study assessment.
Publication Information Expand/Collapse
2014
Enhancing nurse contributions to SWOG clinical trials
PMid: PMID24559777 | PMC number: PMC3961058
Other Clinical Trials
SWOG Clinical Trial Number
S2302
PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
95%
Open
Phase
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open